Skip to main content

IP Update: Recent RNAi- and microRNA-Related Patents and Patent Applications: Aug 18, 2011

Premium

Title: siRNA Targeting Beta Secretase

Patent Number: 7,999,097

Filed: Aug. 17, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE.”


Title: Methods and Compositions for Selecting siRNA of Improved Functionality

Patent Number: 8,000,902

Filed: June 11, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”


Title: microRNA Detection

Patent Number: 7,998,677

Filed: Feb. 26, 2009

Lead Inventor: Christine Esau, Regulus Therapeutics

The invention, the patent's abstract states, comprises “methods for detection of miRNA in a sample. In certain embodiments, the sample comprises RNA and is derived from a cell or tissue. The methods of detection employ a competitor molecule to allow for detection of an miRNA in the presence of an anti-miRNA oligonucleotide.”


Title: Methods, Compositions, and Systems for Local Delivery of Drugs

Application Number: 20110195123

Filed: June 28, 2009

Inventor: Amotz Shemi, Silenseed

The invention relates to an “implantable medical device eluting drug locally and in prolonged period,” according to the patent application's abstract. The device comprises a “polymeric substrate, such as a matrix, for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging."

Drugs are "released directly to the extracellular matrix of the diseased area such as tumor, inflammation, degeneration, or for symptomatic objectives, or to injured smooth muscle cells, or for prevention,” it adds. “One kind of drug is ... based on RNA interference.”


Title: Compositions and Methods for Silencing Apolipoprotein B

Application Number: 20110195127

Filed: June 30, 2010

Lead Inventor: Amy Lee, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention “provides compositions and methods for the delivery of interfering RNAs that silence ApoB expression to liver cells,” the patent application's abstract states. “In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the ... invention are highly potent, thereby allowing effective knock-down of ApoB at relatively low doses. In addition, the compositions and methods of the ... invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.”


Title: Compositions and Methods for Inhibiting Expression of IKK2 Genes

Application Number: 20110196016

Filed: Feb. 1, 2011

Lead Inventor: Anke Geick, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of an IKK2 gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an IKK2 gene using said pharmaceutical composition; and methods for inhibiting the expression of IKK2 in a cell.”


Title: DNA Molecule for Expressing Hairpin RNA, the Constructing Method, and the Use Thereof

Application Number: 20110196142

Filed: Sept. 4, 2008

Lead Inventor: Lei Wang, Chinese Academy of Agricultural Sciences

The patent application, its abstract states, claims a “DNA molecule for expressing hairpin RNA, the constructing method, and the use thereof. … The DNA molecule is a closed single-strand cyclic DNA molecule which is constructed by linking four fragments A, B, C, and D [in the] order A-C-B-D or A-D-B-C, wherein A is a sense strand or antisense strand fragment of the target double-strand DNA; B is the fragment which is reversely complementary to A; C and D are DNA fragments with stem-loop structure.

“The DNA molecule for expressing hairpin RNA and its constructing method are useful in constructing [an] shRNA library,” the abstract adds.


Title: Delivery Method

Application Number: 20110197292

Filed: Dec. 10, 2010

Inventor: Bruce Sullenger, Duke University

The invention, the patent application's abstract states, relates to “RNA silencing and, in particular, to a method of effecting targeted delivery of an RNA silencing moiety using a targeting moiety that binds to a cell surface receptor and mediates internalization of the RNA silencing moiety to be accessible to Dicer. Also provided is a chimeric nucleic acid molecule comprised of a targeting moiety and an RNA silencing moiety, wherein the targeting moiety is an aptamer and the RNA silencing moiety comprises a Dicer substrate.”

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.